Compare AVIR & NMAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVIR | NMAI |
|---|---|---|
| Founded | 2012 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 429.1M | 458.6M |
| IPO Year | 2020 | N/A |
| Metric | AVIR | NMAI |
|---|---|---|
| Price | $5.84 | $14.58 |
| Analyst Decision | Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $10.00 | N/A |
| AVG Volume (30 Days) | ★ 211.4K | 85.4K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 13.14% |
| EPS Growth | ★ 3.00 | N/A |
| EPS | N/A | ★ 0.64 |
| Revenue | ★ $351,367,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.78 | $11.99 |
| 52 Week High | $6.45 | $15.06 |
| Indicator | AVIR | NMAI |
|---|---|---|
| Relative Strength Index (RSI) | 67.99 | 53.39 |
| Support Level | $5.13 | $13.48 |
| Resistance Level | $6.37 | $15.06 |
| Average True Range (ATR) | 0.22 | 0.21 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 94.70 | 52.53 |
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.
Nuveen Multi-Asset Income Fund is a closed-end management investment company. The Fund dynamically invests in a portfolio of equity and debt securities of issuers located around the world. This dynamic investment uses a risk-based framework in which any amount can be allocated to an asset-class at any time. The Fund's investment objective is to provide total return through high current income and capital appreciation.